Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
Leukemia|February 21, 2020
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative StudySabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, et al.
Blood Advances|October 17, 2024
Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemiaRomane Joudinaud, Augustin Boudry, Laurène Fenwarth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS StudyArnaud Pigneux, Marie C Béné, Philippe Guardiola, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Blood|February 11, 2012
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS studyBruno Lioure, Marie C Béné, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Pageof 15